Aon PLC vs Bristol-Myers Squibb Co — how do they compare? Aon PLC trades at $351.31 (market cap $75.61B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AON | BMY | |
|---|---|---|
Market Cap | $75.61B | $129.94B |
Sector | Financials | Health |
52-Week High | $381.26 | $65.89 |
52-Week Low | $308.22 | $42.60 |
Enterprise Value | $90.22B | $163.92B |
Dividend Yield | 0.92% | 3.96% |
Signals from Pluang's Aura AI — not financial advice
AON trades at $356.97, down 0.37% with neutral technical signals. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $3.81 versus $3.80 expected, marking the third consecutive quarterly beat. Revenue growth accelerated to 5% organic in Q2 2026, while margins expanded 70 basis points. Analyst consensus price target stands at $410, representing 15% upside potential from current levels.
AON presents a compelling investment case with consistent earnings outperformance and robust profitability metrics including 44.88% ROE. However, premium valuation multiples and modest organic growth create headwinds. The stock offers 15% upside to consensus targets but requires monitoring of valuation compression risks amid competitive insurance brokerage markets.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →